Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World
At CROI 2026, much of the discussion around antiretroviral therapy focused on long-acting agents and treatment optimization in experienced populations. Yet another important presentation turned to the starting point of care: initial therapy in people newly diagnosed with HIV.
25 veebruar 2026 13:00
Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV
At CROI 2026, among presentations focused on prevention strategies and new antiviral approaches, one oral session addressed a different — and very practical — question in HIV care: what about people who are already virologically suppressed but remain on complex, ...
Lugege edasi
24 veebruar 2026 15:00
Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control
At CROI 2026, alongside discussions of metabolic therapies and inflammation, another plenary session brought the audience back to a more familiar reality. In her lecture, “Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control,” ...
Lugege edasi
Mis on Life4me+?
Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine. Seepärast räägime HIVist ja muudest haigustest — sellest, kuidas end nende eest kaitsta ja kuidas elada nakatununa.
Rohkem
Kampaania Life4me+
Info haridusliku kampaania "M = M" kohta ("Mittetuvastatav = mitteedasikanduv", #UequalsU, #НравноН), mis on Life4me+ poolt organiseeritud Ida-Euroopas ja Kesk-Aasias regioonis, suunatud info levitamisele, et HIV-positiivne inimene mittetuvastatava viiruskoormusega ei saa viirust seksuaalsel teel edasi kanda teisele inimesele.
Mitmed uuringud on näidanud, et diskordantses paaris, kus HIV-positiive partner võtab ARV ravimeid ja hoiab viiruskoormuse mittetuvastataval tasemel, ei ole teada juhtumitest, kus HIV oleks seksuaalsel teel edasi kandunud.
Meie partnerid
